NOVEL FORMS OF BRAIN STIMULATION & PSYCHEDELIC ASSISTED PSYCHOTHERAPY
With
Professor Paul Fitzgerald,
Director, School of Medicine and Psychology,
Australian National University, Canberra, Australia &
Principal Investigator, Paratus Clinical, Australia
RESEARCHER PROFILE
Filmed in Canberra, Australia | November 2025
Professor Paul Fitzgerald is the Head of the School of Medicine and Psychology at the Australian National University. He is an academic psychiatrist with a MBBS degree, Masters of Psychological Medicine and research PhD.
He has conducted an extensive range of experimental studies and clinical trials, focused on the development of novel treatment options for patients with mental health conditions such as depression, schizophrenia, obsessive compulsive disorder, PTSD, autism and Alzheimer’s disease.
Professor Fitzgerald has a special interest in repetitive transcranial magnetic stimulation (rTMS) and other novel treatments using forms of non-invasive brain stimulation. He has had continual NHMRC grant support for 20 years and over $10 million in research support in the last 5 years. He has published several books, over 550 journal articles and been cited over 30,000 times.
He has established multiple clinical rTMS services, founded several device and clinical service companies and led a national application to MSAC in the Federal Department of Health which resulted, in 2021, in Medicare funding ($280 million in year 1) for rTMS therapy for patients with depression.
Professor Fitzgerald currently leads an innovative school at the ANU which combines both the ANU Medical Program and former Research School of Psychology focussed on education and research approaches integrating perspectives across mind, body and culture.
Source: Supplied
https://orcid.org/0000-0003-4217-8096
-
Pathogenicity, modelling & treatment of inherited retinal Stargardt disease
Dr Di Huang is a Research Associate at the Lions Eye Institute (LEI), working with A/Professor Fred Chen and Dr Sam McLenachan. Her research focuses on developing a robust platform of retinal pigment epithelium cells and retinal organoids derived from patient-specific induced pluripotent stem cells to model inherited retinal diseases, particularly Stargardt disease (STGD1).
-
Nuclear medicine & theranostics for molecular imaging & targeted therapy
Dr Aviral Singh is a globally renowned Nuclear Medicine Physician with special interest in Theranostics.
Dr Singh is based in Perth, Western Australia since 2024 and serves as the Clinical Head of Theranostics and Nuclear Medicine at GenesisCare Australia. He is also a Consultant Nuclear Medicine Physician at Fiona Stanley and Royal Perth Hospitals, in addition to pursuing national and international consulting physician roles as Director at Infinity Theranostics.
-
Touched by bowel cancer and chasing science outcomes
Dr Josephine Wright is a Senior Research Fellow in the Gut Cancer group. She has been developing a translational network of labs, hospitals and clinics to enable validation of new approaches to prevent and treat colorectal and gastric cancer. Her key focus is studying human tumour organoids to better personalise therapy in cancer.
